XPEL vs. CPRX
XPEL (XPEL, Inc.) and CPRX (Catalyst Pharmaceuticals, Inc.) are both stocks. XPEL operates in Auto Parts (Consumer Cyclical), while CPRX operates in Biotechnology (Healthcare). Over the past 10 years, XPEL returned 46.22%/yr vs 44.45%/yr for CPRX. At a 0.10 correlation, their price movements are largely independent.
Performance
XPEL vs. CPRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, XPEL achieves a -7.91% return, which is significantly lower than CPRX's 34.53% return. Both investments have delivered pretty close results over the past 10 years, with XPEL having a 46.22% annualized return and CPRX not far behind at 44.45%.
XPEL
- 1D
- 0.37%
- 1M
- 2.80%
- YTD
- -7.91%
- 6M
- -11.92%
- 1Y
- 27.24%
- 3Y*
- -16.94%
- 5Y*
- -12.15%
- 10Y*
- 46.22%
CPRX
- 1D
- 0.06%
- 1M
- 0.45%
- YTD
- 34.53%
- 6M
- 29.59%
- 1Y
- 41.95%
- 3Y*
- 33.66%
- 5Y*
- 39.71%
- 10Y*
- 44.45%
XPEL vs. CPRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
XPEL XPEL, Inc. | -7.91% | 24.96% | -25.83% | -10.34% | -12.04% | 32.43% | 251.95% | 140.10% | 335.82% | 0.00% |
CPRX Catalyst Pharmaceuticals, Inc. | 34.53% | 11.84% | 24.15% | -9.62% | 174.74% | 102.69% | -10.93% | 95.31% | -50.90% | 272.38% |
Correlation
The correlation between XPEL and CPRX is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.15 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.28 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.32 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.18 |
Correlation (All Time) Calculated using the full available price history since Jul 18, 2007 | 0.10 |
The correlation between XPEL and CPRX shifts across timeframes, from 0.10 (all time) to 0.32 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
XPEL:
$1.27B
CPRX:
$3.98B
XPEL:
$1.91
CPRX:
$1.74
XPEL:
24.01
CPRX:
18.05
XPEL:
1.67
CPRX:
0.32
XPEL:
2.60
CPRX:
6.69
XPEL:
4.35
CPRX:
3.93
XPEL:
$489.75M
CPRX:
$596.96M
XPEL:
$208.35M
CPRX:
$378.23M
XPEL:
$78.35M
CPRX:
$313.50M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
XPEL vs. CPRX — Risk / Return Rank
XPEL
CPRX
XPEL vs. CPRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for XPEL, Inc. (XPEL) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| XPEL | CPRX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.61 | ||
| Sortino ratioReturn per unit of downside risk | -0.67 | ||
| Omega ratioGain probability vs. loss probability | 1.15 | 1.25 | -0.11 |
| Calmar ratioReturn relative to maximum drawdown | 0.86 | 3.03 | -2.17 |
| Martin ratioReturn relative to average drawdown | 1.98 | 7.92 | -5.94 |
Loading charts...
Drawdowns
XPEL vs. CPRX - Drawdown Comparison
The maximum XPEL drawdown since its inception was -99.44%, which is greater than CPRX's maximum drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for XPEL and CPRX.
Loading charts...
Drawdown Indicators
| XPEL | CPRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.44% | -94.25% | -5.19% |
Max Drawdown (1Y)Largest decline over 1 year | -31.79% | -13.91% | -17.88% |
Max Drawdown (3Y)Largest decline over 3 years | -71.47% | -27.29% | -44.18% |
Max Drawdown (5Y)Largest decline over 5 years | -75.62% | -45.37% | -30.25% |
Max Drawdown (10Y)Largest decline over 10 years | -75.62% | -64.87% | -10.75% |
Current DrawdownCurrent decline from peak | -54.67% | 0.00% | -54.67% |
Average DrawdownAverage peak-to-trough decline | -52.41% | -51.90% | -0.51% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.79% | 5.32% | +8.47% |
Volatility
XPEL vs. CPRX - Volatility Comparison
XPEL, Inc. (XPEL) has a higher volatility of 8.45% compared to Catalyst Pharmaceuticals, Inc. (CPRX) at 0.46%. This indicates that XPEL's price experiences larger fluctuations and is considered to be riskier than CPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| XPEL | CPRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.45% | 0.46% | +7.99% |
Volatility (6M)Calculated over the trailing 6-month period | 29.51% | 22.84% | +6.67% |
Volatility (1Y)Calculated over the trailing 1-year period | 40.15% | 32.65% | +7.50% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 54.71% | 47.79% | +6.92% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 63.38% | 60.09% | +3.29% |
Dividends
XPEL vs. CPRX - Dividend Comparison
Neither XPEL nor CPRX has paid dividends to shareholders.
Financials
XPEL vs. CPRX - Financials Comparison
This section allows you to compare key financial metrics between XPEL, Inc. and Catalyst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
XPEL vs. CPRX - Profitability Comparison
XPEL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, XPEL, Inc. reported a gross profit of 51.23M and revenue of 117.35M. Therefore, the gross margin over that period was 43.7%.
CPRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 149.39M. Therefore, the gross margin over that period was 0.0%.
XPEL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, XPEL, Inc. reported an operating income of 13.01M and revenue of 117.35M, resulting in an operating margin of 11.1%.
CPRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported an operating income of 73.23M and revenue of 149.39M, resulting in an operating margin of 49.0%.
XPEL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, XPEL, Inc. reported a net income of 10.35M and revenue of 117.35M, resulting in a net margin of 8.8%.
CPRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a net income of 63.73M and revenue of 149.39M, resulting in a net margin of 42.7%.
Frequently Asked Questions
XPEL and CPRX have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
XPEL has higher volatility (8.45%) compared to CPRX (0.46%). In terms of maximum drawdown, XPEL dropped -99.44% vs CPRX's -94.25%.
CPRX currently has the higher Sharpe Ratio (1.29 vs 0.68), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for XPEL and CPRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer